Sun Pharmaceutical Industries Limited (SUNPHARMA) Earnings Call Transcripts

Sun Pharmaceutical Industries Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Sun Pharmaceutical Industries reported a revenue of INR 145,598 million, reflecting a 13.6% year-over-year growth, while net profit reached INR 27,140 million. The company maintained its strong gross margin at 80.8%, but EBITDA margins declined to 27.1%, attributed to increased spending and lower milestone income. Management provided guidance for FY '27, expecting high single-digit revenue growth and R&D spending to remain at 6-7% of sales, indicating a cautious but steady outlook for the upcoming fiscal year.

Reported metrics

Guidance from management

Management expects high single-digit consolidated top line growth for FY '27 and R&D spending to be maintained at 6-7% of sales, indicating a cautious outlook amidst competitive pressures.

What management said

Yes. We have Ilumya and Odomzo, these are 2 products outside the U.S. So if you remember, a couple of quarters back, I said like Ilumya, we launched in 35 countries. Now it has gone to 40 countries, and it is helping us to grow. At the same time, even the other non-Ilumya portfolio is also continuing to grow, and we see that they are adding to the overall growth of the market ex U.S. So overall, I would say the innov...

Yes. Thank you for the question. So for '26, we did see good growth for Ilumya, but we really saw good growth across our Innovative Medicines portfolio. So it really wasn't singled out just to 1 brand. And certainly, if we look at this current fiscal year end and the 1 we're coming into, we expect to see continued growth from aluminum. We still see good growth of the IL-23 market, as KirThank you mentioned earlier, w...

What analysts pressed on

Analysts expressed concerns regarding the sequential decline in EBITDA margins and the impact of increased competition in the U.S. generics market. There were also questions about the integration process of the Organon acquisition and its potential synergies.

Main topics on the call

• Revenue Growth — Sun Pharma achieved a revenue of INR 145,598 million in Q4 FY '26, marking a 13.6% increase from the previous year. Management noted, 'We expect high single-digit consolidated top line growth for FY '27.'
• EBITDA Margin Decline — EBITDA margins fell to 27.1% from 28.7% YoY, primarily due to elevated spending in certain geographies and lower milestone income. CFO Jayashree Satagopan stated, 'We should see some amount of normalization as we go forw...
• Strong Gross Margin — The gross margin for Q4 FY '26 was reported at 80.8%, an improvement attributed to a better product mix. This reflects the company's ability to maintain profitability despite challenges in other areas.
• Acquisition of Organon — Management confirmed the ongoing integration of Organon, emphasizing its complementary nature to Sun Pharma's existing business. The acquisition is expected to be completed in Q4 FY '27, enhancing growth opportunities.

Read the full Sun Pharmaceutical Industries Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 25 Sun Pharmaceutical Industries Limited earnings call transcripts on record, spanning May 27, 2020 to July 31, 2026. Based on this history, Sun Pharmaceutical Industries Limited reports quarterly. The most recent call on file is dated July 31, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SUNPHARMA

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

25

First call

May 27, 2020

Most recent

July 31, 2026

Reporting cadence

quarterly